Venus Remedies Secures Marketing Approval For Three Oncology Drugs

Venus Remedies, a pharmaceutical company, announced that three oncology medications have been approved for marketing in the Philippines and Saudi Arabia. The Panchkula-based business said in a statement that it has acquired regulatory permission for chemotherapeutic drugs paclitaxel and zoledronic acid in the Philippines, the second largest market in the Association of Southeast Asian Nations (ASEAN) region.

The company also secured marketing authorization from Saudi Arabia, the largest pharmaceutical market in the Gulf Cooperation Council (GCC) region, for another oncology drug, bleomycin, as per economic times. 

By 2026, the Philippines' pharmaceutical market is estimated to be worth USD 4.917 billion. The Saudi pharmaceutical market, on the other hand, is predicted to expand to USD 7.19 billion by 2028, according to the report.

Terming the marketing authorisations from Philippines and Saudi Arabia as a significant achievement, Saransh Chaudhary, president, Global Critical Care, Venus Remedies Ltd said, "these marketing approvals are an endorsement of our regulatory prowess and uncompromising quality in line with rigorous global standards, making us a prominent supplier of the three drugs in 15 countries."

Aditi K Chaudhary, president of the company's International Business wing, emphasised the strategic importance of these regulatory milestones, saying, "These approvals mark a crucial step in our international expansion strategy. We are proud to contribute to the improvement of healthcare access and outcomes in South East Asia and the Middle East."